Exeliom is a preclinical-stage biopharmarceutical company

whose mission is to harness the therapeutic potential of gut microbiota 

We are committed to developing a new generation of medicines: monoclonal microbial therapies.

We will use our breakthrough translational approach, our unique relationships with our partners and our passion to devise new ways to prevent and treat diseases.

We are scientists from the fields of medicine, drug development, molecular biology, and process engineering.

Benjamin Hadida

Co-founder, Chief Executive Officer

Dr. Philippe Langella

Co-founder, Preclinical Advisor

Prof. Harry Sokol

Co-founder, Clinical Advisor

Prof. Patrick Gervais

Co-founder, Manufacturing Advisor

Our  Partners

© 2019. Exeliom Biosciences, SAS.